title: The distribution of lung cancer across sectors of society in the United Kingdom: a study using national primary care data.
abstract: BACKGROUND
  There is pressing need to diagnose lung cancer earlier in the United Kingdom (UK) and it is likely that research using computerised general practice records will help this process. Linkage of these records to area-level geo-demographic classifications may also facilitate case ascertainment for public health programmes, however, there have as yet been no extensive studies of data validity for such purposes.
  
  
  METHODS
  To first address the need for validation, we assessed the completeness and representativeness of lung cancer data from The Health Improvement Network (THIN) national primary care database by comparing incidence and survival between 2000 and 2009 with the UK National Cancer Registry and the National Lung Cancer Audit Database. Secondly, we explored the potential of a geo-demographic social marketing tool to facilitate disease ascertainment by using Experian's Mosaic Public Sector ™ classification, to identify detailed profiles of the sectors of society where lung cancer incidence was highest.
  
  
  RESULTS
  Overall incidence of lung cancer (41.4/100, 000 person-years, 95% confidence interval 40.6-42.1) and median survival (232 days) were similar to other national data; The incidence rate in THIN from 2003-2006 was found to be just over 93% of the national cancer registry rate. Incidence increased considerably with area-level deprivation measured by the Townsend Index and was highest in the North-West of England (65.1/100, 000 person-years). Wider variations in incidence were however identified using Mosaic classifications with the highest incidence in Mosaic Public Sector ™types 'Cared-for pensioners, ' 'Old people in flats' and 'Dignified dependency' (191.7, 174.2 and 117.1 per 100, 000 person-years respectively).
  
  
  CONCLUSIONS
  Routine electronic data in THIN are a valid source of lung cancer information. Mosaic ™ identified greater incidence differentials than standard area-level measures and as such could be used as a tool for public health programmes to ascertain future cases more effectively.
authors.affiliation: Division of Epidemiology and Public health, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham, NG5 1PB, UK. mcxboi1@nottingham.ac.uk
authors.forename: Barbara
authors.initials: B
authors.lastname: Iyen-Omofoman
authors.forename: Richard B
authors.initials: RB
authors.lastname: Hubbard
authors.forename: Chris J P
authors.initials: CJ
authors.lastname: Smith
authors.forename: Emily
authors.initials: E
authors.lastname: Sparks
authors.forename: Emma
authors.initials: E
authors.lastname: Bradley
authors.forename: Alison
authors.initials: A
authors.lastname: Bourke
authors.forename: Laila J
authors.initials: LJ
authors.lastname: Tata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008175:Lung Neoplasms / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011320:Primary Health Care / Q000706:statistics & numerical data*; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
references.citation: Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):948-55
references.pmid: 21755569
references.citation: Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):76-83
references.pmid: 19065600
references.citation: Fam Pract. 2008 Aug;25(4):215-20
references.pmid: 18550895
references.citation: Eur J Cancer. 1998 Dec;34(14 Spec No):2191-6
references.pmid: 10070286
references.citation: Lancet. 1997 Oct 11;350(9084):1097-9
references.pmid: 10213569
references.citation: Inform Prim Care. 2004;12(3):171-7
references.pmid: 15606990
references.citation: Heart. 2008 Jan;94(1):34-9
references.pmid: 17916661
references.citation: BMC Public Health. 2010 Dec 07;10:755
references.pmid: 21138555
references.citation: Int J Technol Assess Health Care. 1989;5(4):619-30
references.pmid: 2634632
references.citation: Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):579-85
references.pmid: 20131328
references.citation: Lung Cancer. 2011 Apr;72(1):16-22
references.pmid: 20688413
references.citation: Pharmacoepidemiol Drug Saf. 2009 Sep;18(9):807-14
references.pmid: 19551699
references.citation: Aust N Z J Public Health. 2011 Feb;35(1):61-5
references.pmid: 21299702
references.citation: Thorax. 2010 May;65(5):436-41
references.pmid: 20435867
references.citation: BMC Cancer. 2008 Sep 26;8:271
references.pmid: 18822122
references.citation: Cancer Causes Control. 2009 May;20(4):459-71
references.pmid: 19184626
references.citation: Pharmacoepidemiol Drug Saf. 2009 Aug;18(8):730-6
references.pmid: 19479713
references.citation: BMC Fam Pract. 2008 May 18;9:31
references.pmid: 18485242
references.citation: Qual Prim Care. 2008;16(1):49-52
references.pmid: 18700078